Key Factors
-
Focused on Cardinal Well being, Inc.? Listed below are 5 shares we like higher.
-
Cardinal Well being expects adjusted EPS to develop 13%-15% in fiscal 2027, pushed primarily by operating-income progress throughout its enterprise segments. The corporate additionally reiterated its longer-term 12%-14% EPS progress goal and plans $1 billion in share repurchases.
-
Specialty companies stay the first progress engine: after increasing 25% in fiscal 2026, specialty progress is predicted to method double digits, whereas BioPharma Options is concentrating on $1 billion in income by fiscal 2028.
-
Cardinal Well being anticipates continued progress in at-home options and different companies, together with contributions from latest acquisitions, whereas its medical-products division stays targeted on restoration after mitigating a lot of a $450 million tariff influence.
Cardinal Well being (NYSE:CAH) CEO Jason Hollar mentioned the corporate expects fiscal 2027 to increase the broad working momentum it generated in fiscal 2026, with all 5 working segments positioned for what he described as a “constructive” interval.
Talking on the Morgan Stanley World Healthcare Convention, Hollar mentioned the corporate’s fiscal 2027 adjusted earnings-per-share outlook of 13% to fifteen% progress is predicted to be pushed primarily by operating-income progress throughout its three reporting segments and 5 working companies. Cardinal Well being reiterated its longer-term EPS progress goal of 12% to 14%.
→ IonQ and NVIDIA Simply Cracked a Main Quantum Computing Bottleneck
Hollar mentioned fiscal 2026 included sturdy efficiency throughout each revenue and money circulate, although fiscal 2027 progress is predicted to happen at extra normalized charges. He mentioned below-the-line elements will embrace decrease curiosity expense supported by sturdy money circulate, a barely increased anticipated tax price and $1 billion in deliberate share repurchases.
Pharmaceutical and Specialty Progress
Inside Pharmaceutical and Specialty Options, Hollar mentioned generic-drug quantity is predicted to develop barely above the corporate’s regular 2% to three% vary in fiscal 2027. He attributed the outlook to favorable demographics and continued loss-of-exclusivity exercise, though he mentioned progress just isn’t anticipated to match fiscal 2026 ranges.
→ 2 Shares Breaking Out Submit-FOMC With One Factor in Frequent
Specialty was a significant contributor in fiscal 2026, when it grew 25%, aided by acquisitions and buyer wins in BioPharma Options. For fiscal 2027 and past, Cardinal Well being expects specialty progress nearer to a double-digit price.
Hollar mentioned the corporate stays targeted on three specialty platforms: oncology, urology and autoimmune care, together with gastroenterology. He mentioned the non-oncology markets stay extremely fragmented, with an estimated 80% to 90% of physicians in gastroenterology and urology nonetheless unaffiliated with a administration companies group, or MSO.
→ Generac Plugs into Amazon for an $8B AI-Powered Deal
The corporate doesn’t imagine it wants so as to add a fourth specialty platform at this stage, Hollar mentioned. As an alternative, it plans to proceed pursuing bolt-on alternatives that match its current platforms and tradition.
Cardinal Well being’s BioPharma Options enterprise generated greater than 30% progress in fiscal 2026, Hollar mentioned. The corporate beforehand outlined a path to develop BioPharma Options income to $1 billion by fiscal 2028 from $550 million in fiscal 2025, representing a 20% compound annual progress price.
Buyer Relationships and Specialty Alliance
Addressing the upcoming year-end renewal of Cardinal Well being’s distribution contract with CVS, Hollar mentioned the connection is “very sturdy.” He pointed to longer-dated partnerships involving Purple Oak Sourcing, the Averon Sourcing biosimilars three way partnership and IQ Buying for over-the-counter merchandise.
“It’s an all-of-the-above sort of relationship with them,” Hollar mentioned, including that Cardinal Well being believes CVS is receiving sturdy service.
Hollar additionally mentioned integration of Solaris Well being into The Specialty Alliance is progressing as deliberate. The corporate introduced distribution for GI Alliance and Solaris below its umbrella in the course of the second calendar quarter of 2026. Cardinal Well being expects the year-over-year distribution profit to proceed by means of the fourth quarter of fiscal 2027.
He mentioned Solaris and GI Alliance have shared alternatives in doctor recruitment, payer negotiations, infusion companies and ambulatory surgical procedure facilities, whereas additionally having access to Cardinal Well being capabilities in nuclear drugs, at-home options and core distribution.
Coverage, Biosimilars and Medical Merchandise
On drug pricing and Inflation Discount Act-related modifications, Hollar mentioned Cardinal Well being’s fee-for-service mannequin and contractual protections have allowed it to take care of economics when product pricing modifications. He mentioned the corporate expects that framework to stay intact in fiscal 2027 and past.
For Cardinal Well being’s MSO operations, Hollar mentioned drug spending accounts for roughly one-third of income in its bigger urology and GI companies, whereas workplace visits and procedures account for the remaining two-thirds. That diversification, he mentioned, limits the potential impact of coverage modifications on the group.
Hollar characterised biosimilar and generic loss-of-exclusivity alternatives as “a whole lot of singles and doubles” slightly than a single outsized occasion. He mentioned 2026 and 2027 ought to be constructive years for lack of exclusivity, with 2028 and 2029 anticipated to be considerably stronger.
In World Medical Merchandise and Distribution, Hollar mentioned Cardinal Well being confronted a $450 million tariff influence in fiscal 2026 however mitigated about two-thirds by means of sourcing and different working actions. The remaining influence was successfully shared with prospects, he mentioned. The corporate has not applied important pricing associated to commodity prices, although it’s monitoring strain on gas and oil-based inputs.
At-Residence and Different Companies
Cardinal Well being expects its “different” phase to ship 15% to 18% adjusted operating-income progress in fiscal 2027. About 2 share factors of that progress is predicted to come back from the Try Medical acquisition and an anticipated small late-year contribution from AdaptHealth’s diabetes enterprise.
Hollar mentioned the corporate additionally expects advantages from synergies tied to its earlier acquisition of Superior Diabetes Provide Group. Along with at-home options, he cited progress in nuclear drugs, together with theranostics, and enlargement by OptiFreight Logistics into pharmacy merchandise.
Wanting forward, Hollar mentioned Pharmaceutical and Specialty Options will stay Cardinal Well being’s largest funding precedence, significantly specialty companies. At-home options will stay a key space for inorganic funding, whereas World Medical Merchandise and Distribution stays in a turnaround section however has progress potential by means of Cardinal Well being-branded merchandise.
About Cardinal Well being (NYSE:CAH)
Cardinal Well being, Inc is a healthcare companies and merchandise firm that helps the pharmaceutical and medical industries. Its Pharmaceutical and Specialty Options phase distributes branded, generic and specialty prescription drugs, over-the-counter merchandise and shopper well being objects to pharmacies, hospitals, well being techniques and different healthcare suppliers. The phase additionally offers specialty pharmaceutical companies, nuclear and radiopharmaceutical merchandise, and associated assist for producers and suppliers.
By its World Medical Merchandise and Distribution phase, Cardinal Well being manufactures, sources and distributes medical and surgical merchandise, together with gloves, robes, syringes, exam-room provides and different important tools.
This instantaneous information alert was generated by narrative science expertise and monetary knowledge from MarketBeat as a way to present readers with the quickest reporting and unbiased protection. Please ship any questions or feedback about this story to contact@marketbeat.com.
The article “Cardinal Well being Targets 13%-15% EPS Progress as Specialty Momentum Builds” was initially revealed by MarketBeat.
View MarketBeat’s high shares for September 2026.
